Concern about addiction is associated with lower quality of life in patients with osteoarthritis: an exploratory, real-world data analysis
-
Published:2021-07-05
Issue:1
Volume:31
Page:185-191
-
ISSN:0962-9343
-
Container-title:Quality of Life Research
-
language:en
-
Short-container-title:Qual Life Res
Author:
Garrison Louis P.ORCID, Schepman PatriciaORCID, Bushmakin Andrew G.ORCID, Robinson Rebecca L.ORCID, Tive LeslieORCID, Hall JerryORCID, Dzingina MendwasORCID, Jackson JamesORCID, Berry MiaORCID, Cappelleri Joseph C.ORCID, Silverman StuartORCID
Abstract
Abstract
Purpose
To evaluate the relationship between self-reported concerns about becoming addicted to a medication and health-related quality of life (HRQoL) in patients with osteoarthritis (OA).
Methods
This real-world study used patient-level cross-sectional survey data collected from the US Adelphi Disease Specific Programme (DSP). The DSP for OA selected 153 physicians who collected de-identified data on their next nine adult patients with OA. Each patient completed a disease-relevant survey, which included the Likert-scale question, “I am concerned about becoming addicted to my medicine,” (CAA) with responses ranging from “completely disagree” [1] to “completely agree” [5]. HRQoL was measured by the EQ-5D-5L index value and the EQ Visual Analogue Scale (VAS). A set of ordinary least squares regressions using HRQoL measures as outcomes and CAA as a continuous predictor were estimated. Standardized effect size (ES) was used to gauge the magnitude of effects.
Results
A total of 866 patients with OA completed the survey (female, 61.2%; White, 77.7%; mean age, 64.2 years). Of the 775 patients who completed the CAA question, almost one-third responded that they “agree” (18%) or “completely agree” (11%), while 27% responded “completely disagree” and 20% “disagree.” Regression analyses found that patients who have concerns about medication addiction have significantly different EQ-5D-5L index values and EQ VAS scores compared with patients who do not have this concern (p < 0.0001).
Conclusion
Our findings suggest that concern about medication addiction in patients with OA may have an impact on patient HRQoL, with more concerned patients reporting poorer HRQoL outcomes.
Funder
Pfizer Eli Lilly and Company
Publisher
Springer Science and Business Media LLC
Subject
Public Health, Environmental and Occupational Health
Reference33 articles.
1. Cisternas, M. G., Murphy, L., Sacks, J. J., Solomon, D. H., Pasta, D. J., & Helmick, C. G. (2016). Alternative methods for defining osteoarthritis and the impact on estimating prevalence in a US population-based survey. Arthritis Care and Research (Hoboken), 68(5), 574–580. 2. Lawrence, R. C., Felson, D. T., Helmick, C. G., Arnold, L. M., Choi, H., Deyo, R. A., & Gabriel, S. (2008). Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheumatism, 58(1), 26–35. 3. Neogi, T., & Zhang, Y. (2013). Epidemiology of osteoarthritis. Rheumatic Diseases Clinics of North America, 39(1), 1–19. 4. O’Neill, T. W., McCabe, P. S., & McBeth, J. (2018). Update on the epidemiology, risk factors and disease outcomes of osteoarthritis. Best Practice & Research Clinical Rheumatology, 32(2), 312–326. 5. Kotlarz, H., Gunnarsson, C. L., Fang, H., & Rizzo, J. A. (2009). Insurer and out-of-pocket costs of osteoarthritis in the US: Evidence from national survey data. Arthritis and Rheumatism, 60(12), 3546–3553.
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|